TCOG TCOG (1) T1303 A Multicenter Phase III Trial Comparing Induction Chemotherapy Followed by Concurrent Chemoradiotherapy versus Concurrent Chemoradiotherapy Alone in Stage IV Nasopharyngeal Carcinoma (NPC). 480 MEPFL 480 2003 8 2009 8 T1303 1 342 2 8 81 2 26 6 8 3 1 480 T1303 2009 8 480 (2) T1405 A Phase II Study of Concurrent Chemoradiation for the Localized Nasal NK/T-cell Lymphoma. 30 NK/T EBV DNA lymphoma NFkB 33 2006 5 2009 9 T1405 2 1 2 6 5 4 1 8 2 1 1 33 T1405 98 3 30 30 4 20 33 33 6 TCOG 2009.10
(3) T3206 Multicentre, Prospective Study of First-line Antibiotic Therapy for Early-stage Low-grade and High-grade Gastric Mucosa-associated Lymphoid Tissue-type Lymphoma and Potential Predicting Factor for Treatment Outcome. 25 (1) MALT (2) NF-κB BCL-10 IHC MALT Hp (3) MALT t(11;18) (4) CYP 2C18/2C19 Hp 21 2006 10 2009 9 T3206 13 2 3 2 1 21 T3206 2009 4 (4) T1406 High-dose Methotrexate Plus Steroid Followed by Concurrent Whole Brain Chemoradiation with Temozolomide for Immunocompetent Patients with Primary Central Nervous System Lymphoma A Phase II Study. 25 (1) (2) (3) 4 2006 11 2009 9 T1406 2 1 1 4 T1406 NIRB IRB (5) T1706 Multiple Centers, Prospective, Phase II Trial of Gemcitabine and Docetaxel Combination Chemotherapy in Patients with Locally Advanced/ Metastatic Soft Tissue Sarcoma or Imatinib Mesylate Refractory Advanced/ TCOG 2009.10 7
Metastatic Malignant Gastrointestinal Stromal Tumor. 58 (1) gemcitabine docetaxel / imatinib mesylate (2) (3) imatinib mesylate c-kit PDGFRA c-kit PDGFRA 55 2006 12 2009 9 T1706 4 9 2 6 9 3 3 17 2 55 T1706 3 (6) T1206 A Randomization Trial of Adjuvant Lamivudine/Adefovir Dipivoxil Against Recurrence in Post-operative HBV-related Hepatocellular Carcinoma. 309 94 2007 4 2009 9 T1206 11 1 4 10 14 7 11 16 4 5 4 7 94 (7) T1306 A Phase II/III Randomized Study of Adjuvant Anti-angiogenesis Therapy for Patients of High-risk Oral Cavity Cancer. 448 (1) (2) (3) 95 2007 5 2009 9 8 TCOG 2009.10
T1306 53 1 17 20 2 2 95 (8) T2207 A Phase II Trial of Celecoxib with Preoperative Chemoradiation for Locally Advanced Rectal Cancer. 48 Celecoxib Tegafur-uracil folinate 26 2008 7 2009 9 T2207 6 1 7 2 8 2 26 T2207 2009 2 23 withdraw 3 26 pathology response (9) T3207 A Randomized Phase III Study of Adjuvant Gemcitabine versus Gemcitabine Plus Concurrent Chemoradiation in Pancreatic Cancer Underwent Curative Intent (R0/R1) Resection. 265 gemcitabine 9 2009 2 2009 9 T3207 2 1 3 2 1 9 T3207 NIRB IRB 2009 2 (10) T1408 Incidence of Hepatitis B Reactivation in Non-Hodgkin s Lymphoma Patients Who Receive Rituximab-containing Chemotherapy and are Previously Infected with Hepatitis B Virus. TCOG 2009.10 9
150 rituximab-chop B rituximab-chop 16 2009 6 2009 9 T1408 4 4 2 3 2 1 16 T1408 NIRB IRB 2009 6 (11) T1209 A Phase I/II Study of Sorafenib with Combination of Thalidomide in Advanced or Metastatic Hepatocellular Carcinoma. 77 sorafenib (Nexavar ) thalidomide (Thado ) thalidomide (Thado ) 3 2009 8 2009 9 T1209 3 3 T1209 NIRB IRB 2009 8 (12) T1309 A Phase II Study of Neoadjuvant Bio-chemotherapy with Cetuximab, Paclitaxel, and Cisplatin (CPC) Followed by Cetuximab-based Concurrent Bio-radiotherapy in High-risk Locally Advanced Oral Squamous Cell Carcinoma (OSCC). 47 0 2009 9 2009 9 10 TCOG 2009.10
TCOG 臨床試驗報導 T1309 計畫已經 NIRB 及中國 彰基 成大 永康奇美 柳營奇美等五家醫院 IRB 審 查通過 於 2009 年 9 月開始執行 請各院醫師支持進案 二 即將開始進行之研究計畫 (1) T2209 A Phase II Randomized Study of Induction Chemotherapy Followed by Concurrent Chemo-radiotherapy in Locally Advanced Pancreatic Cancer. 此計畫由胰臟癌工作群 國衛院常慧如醫師及成大沈延盛醫師主持 預計四年完成總需 個案數 73 例 研究目的 比較單一或三種化學藥物併用的兩組引導式化學治療 對胰臟癌病患無病存 活期的影響 計畫進度 此計畫已送 NHRI IRB 及各院 IRB 審查中 TCOG 通訊 2009.10 11